Intas launches biosimilar version of Rituximab Times of India This biosimilar version of Rituximab, competent in treating diseases characterized by excessive numbers of B cells, overactive B cells or dysfunctional B cells like chronic lymphocytic leukemia and rheumatoid arthritis apart from NGL. Mabtas is ... Intas launches low cost drug for cancer treatment |
